Because precision medicine is highly dependent on the accurate detection of biomarkers, there is an increasing need for standardized and robust technologies that measure RNA biomarkers in situ in clinical specimens. While grind-and-bind assays like RNAseq and quantitative RT-PCR enable highly sensitive gene expression measurements, they also require RNA extraction and thus prevent valuable expression analysis within the morphological tissue context. The in situ hybridization (ISH) assay described here can detect RNA target sequences as short as 50 nucleotides at single-nucleotide resolution and at the single-cell level. This assay is complementary to the previously developed commercial assay and enables sensitive and specific in situ detection of splice variants, short targets, and point mutations within the tissue. In this protocol, probes were designed to target unique exon junctions for two clinically important splice variants, EGFRvIII and METΔ14. The detection of short target sequences was demonstrated by the specific detection of CDR3 sequences of T-cell receptors α and β in the Jurkat T-cell line. Also shown is the utility of this ISH assay for the distinction of RNA target sequences at single-nucleotide resolution (point mutations) through the visualization of EGFR L858R and KRAS G12A single-nucleotide variations in cell lines using automated staining platforms. In summary, the protocol shows a specialized RNA ISH assay that enables the detection of splice variants, short sequences, and mutations in situ for manual performance and on automated stainers.
Introduction
High-throughput transcriptomic technologies such as microarrays and next-gen RNA sequencing (RNAseq) have exponentially improved the discovery of RNA biomarkers with diagnostic, prognostic, and predictive clinical value for various diseases including cancer 1, 2 . To advance the use of these biomarkers in precision medicine, there is a high need for standardized and robust technologies that can measure RNA biomarkers within the tissue context of clinical samples. While widely established grind-and-bind assays like RNAseq and quantitative RT-PCR enable highly sensitive gene expression measurements, the required tissue homogenization and RNA isolation imply the loss of in vivo cell-type specificity and morphological information 3 . Conventional in situ RNA detection methodologies lack the sensitivity and specificity required to reliably measure rare or low-expressing RNA biomarkers within the tissue context 4 .
A commercial in situ hybridization (ISH) assay (e.g., the RNAscope assay) is one technology that has tackled these challenges and also enables the highly sensitive and specific visualization of single RNA molecules greater than 300 nucleotides within the tissue morphological context. This type of assay uses a unique oligonucleotide probe design of approximately 6-20 double-Z probe pairs combined with an advanced hybridizationbased signal amplification 5 . This study describes a specialized RNA ISH assay, BaseScope, complementary to the previously designed commercial technology that can detect RNA target sequences as short as 50 nucleotides at single nucleotide resolution. This assay addresses the intricate complexities of the transcriptome and is applicable for the accurate detection of exon junctions, short target sequences, and point mutations in the tissue context ( Table 1 ) using as little as one double-Z probe pair. This report demonstrates the complete assay protocol and its use in the detection of splice variants, CDR3 sequences for T-cell receptor clones, and single-nucleotide mutations in FFPE cell lines and tumor tissues.
Protocol
The human tumor samples used in this study were deidentified and acquired from commercial sources in accordance with the local ethical guidelines for human research.
Probe hybridization
1. Add ~4 drops of the appropriate ready-to-use probe solution to cover the entire section. If using larger sections, add ~5-6 drops. 
Representative Results
The in situ hybridization assay workflow:
The workflow is depicted in Figure 1 and consists of four parts: permeabilization of cells or tissues with target retrieval and protease solutions, hybridization of the probes to the target RNA, signal amplification, and visualization of the signal. The signal can also be quantified using digital imaging software systems or in a semi-quantitative manner based on the number of dots per cell. The manual procedure described in Figure 2 has also been fully automated in commercial auto-staining systems.
Representative staining for exon junction detection (EGFRvIII splice variant): EGFRvIII is a variant of the epidermal growth factor receptor that arises from an in-frame genomic deletion of exons 2 to 7, leading to constitutively active oncogenic signaling 7 . The assay was used to identify EGFRvIII status in FFPE glioblastoma (GBM) tumor samples. Single double-Z probes were designed to span the exon junctions in order to detect either WT, mutant, or both transcripts ( Figure 3A) . The WT EGFR probes span the junctions of either exons 1 and 2 (E1/E2) or exons 7 and 8 (E7/E8), while the EGFRvIII-specific probes span the junction of exons 1 and 8 (E1/E8). A common probe that spans the junction of exons 8 and 9 (E8/E9) was also used to detect total EGFR (both WT and EGFRvIII transcripts). All the probes were then used to determine EGFR status in FFPE GBM samples. The two representative examples shown in Figure 3B were taken from a larger study. EGFR status was confirmed by an independent method, RT-PCR. Both WT probes detected signal in both samples, indicating that the two samples express WT EGFR ( Figure 3B) . However, the mutant probe only showed signal detection in the EGFRvIII+ sample, confirming that this sample is indeed positive for the EGFRvIII variant ( Figure 3B, left panels) . Conversely, the mutant probe did not detect signal in the EGFRvIII-sample ( Figure 3B , right panels). Taken together, these results demonstrate that the exon junction assay can identify EGFRvIII status in GBM FFPE tumor samples.
Representative staining for short targets: The CDR3, or complementary determining region 3, is a highly variable domain in T-cell receptors. Typically, the CDR3 sequence are quite short; for example, the CDR3 α and β sequences from the Jurkat T-cell line are 51 and 48 nucleotides in length, respectively ( Figure 4A) . To identify the specific CDR sequences expressed in Jurkat cells, antisense probes for CDR3 α and β that are expressed in the Jurkat T-cell line were generated, in addition to sense probes for CDR3 α and β to serve as negative control probes. All the probes were then tested in FFPEprepared Jurkat cells with the assay. Robust staining was observed with anti-sense probes for both CDR3 α and β in the Jurkat cells, whereas sense probes detected little to no signal ( Figure 4B ). These results demonstrate the ability of the short target assay to discern between highly variable but short CDR sequences for T-cell receptor clones.
Representative staining for point mutation EGFR L858R: Point mutation probes were developed to detect single nucleotide variations and small insertions or deletions (INDELs) in the tumor context. Figure 5A demonstrates the ability for in situ detection of the point mutation EGFR L858R (2573T>G). Two probes were designed: one to detect the L858R mutated EGFR sequence, and another to detect the EGFR L858 WT sequence. Both probes were tested in two FFPE-prepared cell lines: H2229, which only expresses EGFR L858 WT; and H1975, which is heterozygous for the EGFR L858R mutation. The L858R mutant probe detected signal only in the H1975 cell line but not in the H2229 cell line. However, the WT probe detected signal in both cell lines. Similarly, Figure 5B visualizes in situ detection of the point mutation KRAS G12A (35 G>C). Two probes were designed to detect the KRAS G12A MT and KRAS G12 WT sequences and then tested on the HuT78 cell line (which only expresses KRAS G12 WT) and the SW116 cell line (which is heterozygous for the KRAS G12A mutation). While the KRAS G12 WT probe detected signal in both cell lines, the KRAS G12A probe only detected signal in the SW116 cell line. Taken together, these data demonstrate the technical capability of the point mutation assay in detecting single nucleotide polymorphisms in the cell and tissue context.
Representative staining for the automated in situ assay: Automated assays allow for a greater number of samples to be run more reliably, minimizing inter-user variability and hands-on time and generating consistently reproducible results. Therefore, an automated version of the assay was developed. To demonstrate automated staining with this assay, detection of the splice variant METΔ14 was examined. This variant is the result of exon 14 in the MET gene being skipped during pre-mRNA splicing, which leads to constitutive activation and oncogenic transformation of the MET receptor 8, 9 . To specifically detect the METΔ14 variant, two exon junction probes were designed: one that spans the junction of exons 13 and 15 (E13/E15) to detect the METΔ14 variant transcript, and another that spans the junction of exons 14 and 15 (E14/E15) to detect the WT MET transcript ( Figure 6A) . Both probes were then tested in 2 FFPE-prepared cell lines: H596, which expresses the METΔ14 variant, and A549, which expresses the WT MET gene. Both probes showed mutually exclusive expression patterns, with the E13/E15 probe only detecting signal in the H596 cells and the E14/E15 probe only detecting signal in the A549 cells (Figures 6B and 6C) . Lastly, the probe for dapB showed no signal, indicating no background signal (Figures 6B and 6C) . Overall, this data demonstrates specific detection of the MET variant METΔ14 in situ utilizing the automated BaseScope assay. Gene editing Table 1 : Applications of the in situ assay. There are 3 main categories for applications of this assay: exon junction, short target sequence, and point mutation. Listed in each column are some specific application examples for each category.
Discussion
In this report, the novel ISH assay protocol and its applications were discussed in detail. The assay allows for the direct visualization of exon junctions, short-target and highly homologous sequences, and point mutations in the tissue context. The assay is based on RNAscope technology 5 and is therefore capable of single molecule detection. However, due to an advanced amplification system, the signal can be detected with probes containing as little as one double-Z pair or with a target template length of just 50 nucleotides. Because the probes may be as short as a single double-Z in length, this allows for the detection of exon junctions, short-target and highly homologous sequences, and point mutations ( Table 1) For successful performance of the assay, there are several technical recommendations. First, tissues should be fixed in fresh 10% neutralbuffered formalin (NBF) at room temperature for 16-32 h 10 . Underfixation (<16 h) or overfixation (>32 h) will impair performance of the assay and may require additional optimization. Second, to ensure optimal control of temperature and humidity, which are required for robust probe hybridization and signal amplification, the slide processing system and hybridization oven should be used for protocol steps 2.3 to 5 (protease pretreatment, probe hybridization, signal amplification, and signal detection). Third, excess residual buffers should be properly decanted before each step throughout the protocol (but not so much so that the tissue sections dry out). If the slides dry out, significant non-specific signal will develop. Fourth, depending on the tissue type, pretreatment optimization may be necessary. Using the wrong protease or performing for a suboptimal length of time may result in under-or over-digestion and will negatively affect the signal. Lastly, it is important to always run positive and negative controls with the test probes. Negative control probes ensure that there is no background signal, and positive control probes ensure that the assay has been done correctly and that the RNA quality in the sample is optimal for interpreting test probe results. If there is no signal with the positive control probe, then the RNA quality in the sample is likely suboptimal and a signal may not be seen with the test probe.
In addition to the manual assay, the ability to perform the assay on automated stainers was also demonstrated (Figure 6 ). This automated ISH assay yields a high signal-to-noise ratio and is applicable for the same applications as shown in Table 1 ; however, benefits of an automated assay include standardization of assay conditions, minimization of inter-user variability and hands-on time, and allowance for high-throughput screening of tissue samples in a reliable manner.
While immunohistochemistry (IHC) and qRT-PCR allow for detection of splice variants (particularly EGFRvIII), in FFPE clinical specimens, these techniques can lack the necessary specificity and do not offer insight into the spatial resolution of the splice variant expression, respectively 11, 12 . A key advantage of the assay in this protocol is its highly sensitive and specific visualization of splice junctions while preserving the morphological tissue context. Here, the assay's ability to precisely target unique exon junctions for several splice variants, including EGFRvIII and METΔ14, was demonstrated (Figures 3 and 6 ). In addition, the assay has been shown to detect the splice variant AR-V7 in prostate cancer, multiple isoforms of ErbB4 in the brain, and confirmation of knockout of circular RNA Cdr1as in the mouse brain 3, 13, 14 . Short target sequence detection by this ISH assay allows for visualization of RNA sequences as short as 50 nucleotides in length, as demonstrated by the detection of CDR3 sequences derived from Jurkat cells (Figure 3) . The assay can also detect gene sequences that are highly homologous to other family members or species, as shown by Revêchon et al., who used the short target assay to detect human progerin expressed in mouse subcutaneous white adipose tissue 15 . In addition, small nucleolar RNA (snoRNA), CRISPR-mediated gene editing, and precursor-microRNA can be detected in situ with the short target assay. More recently, Fu et al. combined this ISH assay with IHC to identify precise cells in the retina expressing the pre-miRNA mir125b 16 .
Mutation profiling in tumors is critical for studying the progression of tumors and for developing targeted therapies. While mutation profiling can be achieved via high-throughput sequencing, this technology cannot fully address intratumoral heterogeneity or link genetic alterations with cellular morphology 17, 18 . The detection of point mutations using this ISH assay allows for distinction of RNA target sequences at a single-base resolution, as validated by the detection of EGFR L858R and KRAS G12A single nucleotide variations in cell lines ( Figure 5) . Furthermore, Baker et al. used the point mutation assay to target multiple mutations in the BRAF, KRAS, and PIK3CA oncogenes in colorectal cancer 18 . They were able to identify and spatially map rare mutant subclones of tumor cells, ultimately showing how they contribute to intra-tumor heterogeneity.
In summary, a specialized RNA ISH assay has been developed. This methodology allows for the detection of splice variants, short sequences, and mutations in situ. It is sensitive, specific, quantifiable, and adaptable to performance both by manual methods and on automated stainers.
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